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ABSTRACT  
Regardless of so many advancements in the treatment, colon cancer still stands third in cancer-related deaths worldwide. Toxicity associated 
with conventional drugs is one of the major problems associated with chemotherapy. Targeted delivery works by concentrating the medication 
in the tissues of interest and reducing the concentration in remaining tissues. This delivery system helps the drug molecule to reach preferably 
to the desired site. The targeting will lower the requirement of a higher dose of the drug thus reducing the dosage frequency. The present 
review focuses on the various parameters of targeted drug delivery including the criteria for selection of drug and factors affecting the targeted 
drug delivery and also includes the brief discussion about different targeted drug deliveries for colon cancer therapies. 
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1.1 INTRODUCTION 
The foundation of the word ‘cancer’ is attributed to 
‘Hippocrates’ (460-370 B.C.), who is said to be the “Father of 
Medicine”. Hippocrates reported various types of cancer, 
mentioning them by the word karkinos (carcinos), it is the 
Greek expression for crab or crayfish [1,2]. Cancer is a 
ubiquitous disease that is said to be associated with 
excessive mortality cases despite ongoing research. An 
estimated 6.35 million new cases of cancer are diagnosed 
worldwide annually, half of which originates in developing 
nations [3]. Survey of 1998 showed that in India a number of 
cancer patients are about 0.609 million out of which around 
0.315 million are male and 0.294 million are female [4]. 
Cancer is said to be the second major reason for death in the 
world after cardiovascular diseases. Uncontrolled growth of 
cells indicates cancer, resulting in a primary tumor that 
invades and destroys other tissues. It is specified by loss of 
regulatory mechanism which controls cell development and 
maturation required for homeostasis in complex 
multicellular organisms. Normal cells increase their number 
by multiplication when there is body’s requirement and dies 
when the requirement is over [5]. Cancer is generated when 
normal cells in a particular region of the body start to grow 
without any control. The multiplication of cells is controlled 
with care and help in the certain requirements of the body. 
The rate of proliferation for normal mature cells equals the 
rate of cell death, whereas in cancer proliferation exceeds the 
death rate. Abnormal changes in normal cells within the 
body leads to the formation of a lump, called a tumor. There 
are various kinds of cancers; all kinds of cancer cells grow, 
then divide and finally redivide in place of death and result in 
the formation of abnormal cells. Some kinds of cancer cells 
frequently travel to the various region of the body via blood 
circulation or lymph vessels (metastasis), where they start 
their growth and can affect the digestive circulatory and 
nervous system. Cancer generally forms as a solid tumor [2]. 
Tumor cells show a number of features which differs from 
normal cells: 
a) They arean independent growth factor because they 
can secrete their own growth factor to stimulate 
cellular proliferation. 
b) Normal cells require contact with the extracellular 
environment to grow whereas tumor cells are 
independent. 
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c) Normal cells respond to the existence of other cells in 
culture and form a monolayer whereas tumor cells lack 
this characteristic and grow over or under each other. 
d) Normal cells stop proliferation once they achieve a 
certain density but tumor cells continue to multiply [6]. 
Cancers are of various types like Breast cancer, Colon cancer, 
Lungs Cancer, Prostate cancer, etc. In the US the third most 
common cancer found in colorectal cancer. The colorectal 
tumor is also known as colon malignancy is the progression 
of development from the colon or rectum [7]. It is due to the 
abnormal growth of cells that can spread to various regions 
of the body. Signs and side effects may include blood in the 
stool, reduced weight and tiredness [8]. Only a few of 
colorectal diseases are hereditary all others are because of 
life variables.  Absence of physical activity, smoking and 
eating regimen are few of the reasons. Dietary habits that can 
cause danger include red meat and in addition liquor [9]. 
 Colorectal cancer is a disease arising from the epithelial 
cells lining the colon or rectum in the gastrointestinal tract, 
mostly due to the mutations in the Wnt signaling pathway 
that enhances signaling activity[10,11,12]. The mutations 
can be inherited or acquired [13]. APC gene is the mutated 
gene in the case of colorectal cancer, which forms the APC 
protein. The APC protein stops the gathering of β-catenin 
protein [14,15]. Without APC, β-catenin gathers to high 
levels and moves into the nucleus, binds to DNA, and finally, 
the transcription of proto-oncogenes is activated [16]. These 
genes are normally needed for stem cell renewal and 
differentiation, but when expressed at high levels, they can 
result in cancer. Molecular model for the evolution of 
colorectal cancer through the adenoma-carcinoma sequence 
showed by fig1. The mutation occurs in APC in most of the 
colon cancer cases, due to the of mutations in β-catenin there 
is an enhancement in beta-catenin that stops its own 
breakdown, or show mutations in various genes such as 
NKD1, AXIN1, AXIN2 which were having the same function 
as APC [17]. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1: Molecular model for the evolution of colorectal cancer through the adenoma-carcinoma sequence. 
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2.1 Colon Cancer 
Globally, colorectal cancer (CRC) is the second most common 
cancer in women (614, 000 cases per year) and the third 
most common in men (746, 000 cases per year). The 
incidence ratesare much higher in developed countries (737, 
000 cases per year) than in less developed ones (624, 000 
cases per year).  Incidence is much more in men than women 
and it significantly increases with age; median age at 
diagnosis is about 70 years in developed countries [18]. 
Colorectal cancer (CRC) is the third most common type of 
cancer worldwide and a leading cause of cancer death. 
During the development of colorectal adenocarcinomas 
there occur sequential genetic and epigenetic mutations in 
specific oncogenes [19,20] in epithelial cells from 
gastrointestinal tract resulting in the start of CRC onset, its 
progression and metastasis [21]. Early diagnosis and better 
knowledge of the molecular basis of its onset and 
progression are very important in the treatment of CRC. This 
review gives an idea about managing and diagnosis of CRC 
[22]. CRCs occur because of various mechanisms 
combination, including microsatellite instability (MSI), 
chromosomal instability (CIN) and CpG island methylator 
phenotype (CIMP), According to Fearon [23], the classical 
CIN pathway starts with the acquiring mutations in the 
adenomatous polyposis coli (APC), which results in the 
mutational activation of oncogene KRAS and also the tumor 
inactivation suppressor gene, TP53. Aneuploidy and 
deprivation of heterozygosity (LOH) are the major players in 
CIN tumors, which not only constitute the sporadic tumors 
(85%) but also involve familial adenomatous polyposis cases 
associated with germline mutations in the APC gene [24]. 
The CIMP pathway is identified by the promoter 
hypermethylation of different tumor suppressor genes, 
like MGMT and MLH1. This hypermethylation includes the 
BRAF mutation and unstable microsatellite [25]. The MSI 
pathway includes the deactivation of genetic modifications 
in little repeated sequences. This startup takes place in CRCs 
in DNA mismatch repair (MMR) genes. Also, the 
hypermethylation of the MMR genes may result in MSI. This 
mechanism is related to the CIMP pathway [26]. MSI tumors 
are related to proximal colon and poor differentiation but 
good prognosis [27]. Three mechanisms often overlap in 
CRC [23,28,29]. 
2.1.1 Molecular basis of CRC  
During the growth of colorectal adenocarcinoma, epithelial 
cells from gastrointestinal trait obtain sequential genetic and 
epigenetic mutations in particular tumor suppressor genes, 
benefitting them with profit on proliferation [19,20]. The 
normal epithelium will form the hyperproliferative mucosa 
and eventually forms a benign adenoma that results in 
carcinoma and metastasis in around 10 years[21]. 
Sporadic colorectal cancers (CRC), due to somatic mutations, 
makes about 70% of all CRCs. Familial CRC accounts for 
around 10-30% cases whereas hereditary diseases are about 
5-7% [30]. Single-nucleotide polymorphisms (SNPs) in 
oncogene are cause for the familial types of the disease, 
while hereditary CRC is caused by the inactivating mutations 
in the same genes [31,32]. The main hereditary CRC 
syndrome includes adenomatous polyposis syndrome and 
hereditary nonpolyposis colorectal cancer (HNPCC) [33]. 
2.1.2. Hereditary CRC and molecular diagnosis 
 Hereditary CRCs accounts for around 7-10% of CRC and it 
comprises of   HNPCC, adenomatous which includes FAP and 
MAP and hamartomatous which comprises of PJS, JPS, PHTS 
polyposis syndromes [31]. The genes whose modifications 
are present in their onset are now well known in Table 1.
 
Table 1. List of gene mutations in hereditary CRC. 
Syndrome Gene Hereditary 
Hereditary non-polyposis colorectal cancer (HNPCC) MLH1, MSH2, MSH6, MLH3 and PMS2 Dominant 
Turcot Syndrome (TS) MMR or APC Dominant or 
Recessive 
Familial Adenomatous Polyposis (FAP) APC gene Dominant  
MUTYH-associated polyposis (MAP) MUTYH Recessive 
Peutz-Jeghers syndrome (PJS) STK11/LKB1 Dominant 
PTEN hamartoma tumors syndrome (PHTS) PTEN Dominant 
Juvenile polyposis syndrome (JPS)  SMAD4-BMPR1A Dominant 
Polymerase Proofreading-Associated Polyposis (PPAP) POLD1-POLE Dominant 
 
3.1 Cancer Therapy 
There is no permanent treatment for cancer but palliative 
treatments are available. There are many drugs present in 
the market which have the potential to act against cancer. 
Most of the compounds possess anticancer activity but also 
have many side effects. Cancer can be treated by: 
a) Surgery 
b) Chemotherapy 
c) Radiation therapy 
d) Immunotherapy 
e) Monoclonal antibody 
3.1.1 Chemotherapy: 
The term chemotherapy includes the utilization of a huge 
range of drugs for the management of cancer. Their drugs 
generally show their action by killing dividing cells or 
modify their growth. More and more cells are produced, and 
they start to occupy a great amount of space until they 
occupy the space previously inhabited by useful cells. 
Chemotherapy drugs obstruct the division and reproduction 
of cancer cells. A drug can be used alone or the combination 
of drugs can be used. They can be given directly into the 
bloodstream, to attack cancer cells present in the body, or 
they can be targeted to particular cancer regions. 
Chemotherapy drugs can: 
 Dame the mitosis process, or stop cell division. 
 Target the substances needed for the growth of cancer 
cells. 
  Apoptosis. 
 Prevent the growth of new blood vessels that supply 
a tumor in order to starve it. 
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Instead of causing the cells to starve, studies have shown 
that preventing the blood flow may increase the cells ability 
to stop treatment and lead to metastasis. They say it could 
be effective in stopping the cancer cells from opposing the 
treatment as they target the proteins that are deployed by 
cancer to enhance resistance and cause metastasis. 
Chemotherapy drugs can be categorized into different types 
based on the various factors such as their working 
mechanism, chemical structure, and the relationship they 
have with others. Chemotherapeutic agents can be divided 
on the basis of the phase of the cell cycle in which they are 
active.  
3.1.1.2. Cell cycle-specific and non-specific agents: 
Substances that are nonspecific shows a linear dose-
response curve; which means that the more the dose of the 
drug, more is the number of cells that are killed. However, 
cell cycle phase-specific drug has a plateau with respect to 
cell-damaging ability, and cell damage will not increase with 
further increase in drug dosage. 
3.1.1.2.1 Cell cycle-specific agents 
 S phase-dependent: 
Antimetabolites: Capecitabine, Cytarabine, Doxorubicin, 
Fluorouracil, Floxuridine, Hydroxyurea, Mercaptopurine, 
Methotrexate, Prednisone. 
 M phase dependent: 
Vinca alkaloids: Vincristine, Vinblastine, Vinorelbine. 
Podophyllotoxin: Etoposide, Teniposide. 
Taxanes: Docetaxel, Paclitaxel. 
 G2 phase-dependent: 
Bleomycin, Irinotecan, Mitoxantrone, Topotecan. 
 G1 phase-dependent: 
Aspariginase, Corticosteroids. 
3.1.1.2.2. Cell cycle non-specific agents 
Alkylating agents 
Antibiotics 
Cisplatin 
Nitrosoureas 
3.1.2 Combination Chemotherapy: 
Combination chemotherapy means the utilization of more 
than one chemotherapy medication at a time to treat cancer. 
In the past, cancer was often treated with a single drug, but 
current treatments for many types of cancer use a 
combination of two or more different drugs simultaneously. 
It is now said to be the standard of care, especially in cancer 
treatment, since it is a rationale strategy to increase 
response and tolerability and to decrease resistance. 
Combination chemotherapy helps to get the three major 
aims which cannot be attained with single-agent therapy: 
 It damages the cell in the range of toxicity tolerated by 
the host. 
 It gives  the  wide range   for coverage of resistant cell 
lines in a heterogeneous tumor population; and 
 It stops or reduces the growth of new drug-resistant 
cell lines. 
 
 3.1.2.1 Selection of drug for combination chemotherapy 
The following principles have been accepted to help drug 
selection in combination regimens: 
 Drugs which are active as single agents should be 
selected for combinations. Preferably, a drug that 
induces remissions should be taken. 
 Drugs whose mechanisms of action differ should be 
combined in order to allow for additive or synergistic 
effects on the tumor. 
 Drugs with differing dose-limiting toxicities should be 
combined to allow each drug to be given at full or 
nearly full therapeutic doses. 
 Drugs should be taken at regular intervals.  
 Drugs with different patterns of resistance should be 
combined to minimize cross-resistance. 
If given at early stages, chemotherapy can result in complete 
treatment, making the side effects tolerable for many 
patients. A plan is made up that tells about the treatment 
sessions. 
On the basis of the type of cancer, the patient may take 
chemotherapy orally, or intravenously, injected into the vein 
or elsewhere. 
Orally: Tablets can be taken. The drug may also be in 
capsule or liquid form. The dose must be taken exactly when 
specified. 
Intravenous chemotherapy: This can be taken directly into 
a vein with the help of the needle or delivered through an 
intravenous infusion. The drugs can also be given: 
 as an injection in a muscle in the arm, thigh 
 intrathecally which is  injected into the in the  layers of 
tissue that cover the brain and spinal cord 
 as an intraperitoneal (IP) injection,  directly delivered 
where the intestines, stomach, and liver are present 
 intra-arterially (IA), injected into the artery that leads 
to cancer. 
4.1 Targeted Drug Delivery 
The whole idea targeted drugs go back to the year 1906 
when Ehrlich [34] first suggested the ‘magic bullet’. The 
permanence of this idea is a strong sign of its appeal, but the 
‘magic bullet’ is still a challenge to implement in the clinic. 
The problem is with three things; first thing is finding the 
target for a specific disease state; to find a drug that 
efficiently treats this disease; and discovering an idea of 
taking the stable form of the drug while avoiding the 
immunogenic and nonspecific interactions that efficiently 
clear foreign material present in the body [35]. 
Targeted drug delivery includes giving medication to a 
patient in such a way that it enhances the amount of the 
medication in a few parts of the body in comparison to 
others. Targeted drug delivery includes concentrating the 
medication in the tissues of interest while decreasing the 
relative concentration of the medication in the other tissues. 
The drug is administered in such a manner that the drug is 
only active in the targeted area of the body and then the 
drug is released over in a controlled manner e.g., colon 
targeted drug. This enhances efficacy and decreases side 
effects. It is very hard for a drug molecule to reach its 
endpoint in the complicated cellular network of an 
individual. Targeted delivery of drugs helps the drug 
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molecule to reach preferably to the required region. The 
benefit of using this method includes a decrease in dose & 
side effect of the drug. Research associated with the 
development of targeted drug delivery system is nowadays 
highly favored in the pharmaceutical field [36]. 
4.1.1 Types of Targeted Drug Delivery System: 
 Targeting drug to a particular region not only enhances the 
therapeutic efficacy of drugs also it aims to reduce the 
toxicity related with the drug so that the lower doses of the 
drug can be used.  Two approaches are used widely for drug 
targeting [37,38,39]. Active and passive targeted drug 
delivery is diagrammatically showed in fig2. 
4.1.1.1 Passive targeting 
It means drug or drug carrier system gathered at a particular 
region such as anti-cancerous drug whose explanation may 
be credited to pharmacological or physicochemical factors of 
the disease [40]. 
4.1.1.2 Active targeting  
It includes specific ligand-receptor type interaction for 
intracellular localization which results after the 
extravasations and blood circulation [40]. 
1) First-order targeting refers to the confined distribution 
of the drug carrier systems to the capillary bed of a 
fixed organ, tissue. 
2) Second-order targeting means selective delivery of 
drugs to particular cell types such as tumor cells and 
not to the normal cells. 
3) Third-order targeting includes drug delivery 
particularly to the intracellular region of targeted cells 
[38].
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2: Active and passive targeted drug delivery. 
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5.1 Targeted Dosage Form Benefits against 
Conventional Dosage Form 
Chemotherapy is a type of treatment that also shows adverse 
effects. As the drugs often target healthy cells with cancerous 
cells.  
 The conventional dosage forms release the drug 
immediately and it results in the variation of drug level 
in blood. 
 Therefore to conserve the drug amount within 
therapeutic effective range, need for novel drug 
delivery system is there. 
 It provides optimum dose in the right location at the 
right time. 
 Systematic usage of expensive drugs and the excipients 
and decrease in production cost. 
 Improved comfort, better therapy and increased 
standard of living. 
 Reduction in dosing frequency. 
 The decrease in the rate of rising of drug concentration 
in blood. 
 To get a targeted drug release. 
 Decreased side- effects. 
 Fewer chances of missing the dose of a drug having the  
short half-life 
 With the help of concepts and methods of sustained or 
controlled and targeted drug delivery systems, good 
and safer use of existing drugs. 
 Targeted therapy includes specificity towards cancer 
cells while reducing toxicity to other cells. 
 Targeted therapy made to enhance  the effectiveness of 
chemotherapy because it aims specifically at the cancer 
cells’ function that either: 
o Allows cancer cells to continue growing and dividing. 
o Helps to keep the tumor alive. 
 Effectiveness of the therapy includes the targeted 
release of therapeutics at the diseased region while 
reducing the off-target side effects in the normal 
tissues. 
 Targeted therapies give medical oncologists a batter 
method to personalize cancer treatment.  
Advantages of targeted therapy include: 
o Decreased suffering  to normal cells 
o Lesser  side effects 
o Better effectiveness 
o Better quality of life 
6.1 Colon Targeting 
The colon is a site where both local and systemic delivery of 
drugs can take place. Local delivery helps to treat IBD 
topically. The treatment can be made productive if the drugs 
can be targeted directly into the colon, causing a decrease in 
the systemic side effects. 
Targeted drug delivery is needed for local treatment of a 
variety of bowel diseases [41,42]. The colon-specific drug 
delivery system (CDDS) should protect the drug i.e. the drug 
should only be released and absorbed once the system 
reaches the colon.  
The colon is a good absorption site for peptides and protein 
drugs for various reasons; 
(i) less diversity and intensity of digestive enzymes,  
(ii)  Proteolytic activity of colon mucosa is lesser than  in the 
small intestine,  
Thus CDDS save peptide drugs from hydrolysis, and 
enzymatic degradation in duodenum and jejunum, and 
finally  release  the drug into ileum or colon which results in 
more  systemic bioavailability [43] and at last , as  the colon 
has a long residence time of about  5 days and is greatly  
responsive to  enhancers of absorption [44]. 
Possible routes for colon targeting: 
I. Oral route 
II. Rectal route 
The oral route is the preferred route [45]. Oral 
administration of various dosage forms is the most common 
type of administration due to good patient compliance and 
flexibility [46]. Rectal administration provides the shortest 
route for targeting drugs to the colon. Using the rectal route 
to reach to the proximal part of the colon is not easy. 
Delivering the medication through the rectal route can also 
be uncomfortable [47]. Dosage form for intrarectal 
administration includes solutions, foam, and suppositories. 
The intrarectal route is used for systemic dosing and for the 
topically active drug to the large intestine. 
6.1.1 Criteria for Selection of Drug for CDDS: 
The best Candidates for CDDS are drugs which show poor 
absorption from the stomach or intestine including peptides.  
The drugs used in the treatment of IBD, ulcerative colitis, 
diarrhea, and colon cancer are good for local colon delivery 
[48]. The criteria for the selection of drugs for CDDS are 
summarized in Table 2. 
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Table 2: Criteria for selection of drugs for CDDS [49,50,51] 
Criteria Pharmacological class Non-peptide drugs Peptide drugs 
Drugs used for local effects in 
colon against GIT diseases 
Anti-inflammatory drugs 
 
Oxyprenolol, Metoprolol, 
Nifedipine 
Amylin, Antisense 
oligonucleotide 
Drugs poorly absorbed from 
upper GIT 
Antihypertensive and 
antianginal drugs 
Ibuprofen, Isosorbides, 
Theophylline 
Cyclosporine, 
Desmopressin 
Drugs for colon cancer Antineoplastic drugs Pseudoephedrine Epoetin, Glucagon 
Drugs that degrade in the 
stomach and small intestine 
Peptides and proteins Brompheniramine, 
5-Fluorouracil, Doxorubicin 
Gonadorelin, Insulin, 
Interferons 
Drugs that undergo extensive 
first-pass metabolism 
Nitroglycerin and 
corticosteroids 
Bleomycin, Nicotine 
 
Protirelin, sermorelin, 
Saloatonin 
Drugs for targeting 
 
Antiarthritic and 
antiasthmatic drugs 
Prednisolone, hydrocortisone, 
5-Aminosalicylic acid 
Somatropin, Urotoilitin 
 
 
6.1.2 Factors affecting colon targeted drug delivery [52]: 
6.1.2.1 Physiological factors 
6.1.2.1.1 Gastric emptying: 
Drug delivery to the colon upon oral administration depends 
mainly on gastric emptying and bowel transit time. Upon 
reaching the colon the transit time of dosage form depends 
on the size of the particles. Smaller particles have more 
transit time compared to larger particles. Diarrhea patients 
have shorter transit time whereas constipation patients have 
longer transit times. 
6.1.2.1.2 pH of the colon: 
The pH varies significantly between different regions of the 
GIT. For example, the pH of gastrointestinal contents can be 
as low as 1 to 2 in the stomach and rise to 7.5 in the distal 
small intestine [53]. The pH then declines from the end of 
the small intestine to the colon and gradually increases once 
again in the colon. This change in the pH in different parts of 
GIT is the basis for the development of colon targeted drug 
delivery systems. Coating with different polymers is done to 
target the drug to the site.  
6.1.2.1.3 Colonic microflora and enzymes: 
Growth of this microflora is controlled by the GIT contents 
and peristaltic movements. Relation of different microflora 
and enzymes of the colon are listed in table 3 with their 
metabolic reactions. 
  
Table 3: Different microflora, enzymes released and action. 
Microorganism Enzyme Metabolic reaction 
E.coli, Bacteroids Nitroreductase Reduces aromatic & heterocyclic nitro compounds 
Clostridia, Lactobacilli Hydrogenase Reduces carbonyl groups & aliphatic double bonds 
Clostridia, Eubacteria Glucosidase Cleavage of glycosidase of alcohols & phenols 
Eubacteria, Clostridia, Streptococci Sulfatase Cleavage of Osulphates & sulfamates 
 
 
6.1.2.2 Pharmaceutical factors 
6.1.2.2.1 Drug candidates: 
Due to more retention time of colon, a colon makes 
enhancement in the absorption of the drugs that are poorly 
absorbed like peptides and drugs used for the treatment of 
inflammatory bowel diseases, etc. are acceptable for colon 
targeted drug delivery system [46]. 
6.1.2.2.2 Drug carriers: 
The selection of carrier is based on the nature of the drug 
and the disease for which the drug is used [46]. The various 
factors that affect the carrier selection include chemical 
nature, partition coefficient and stability, etc. 
7.1 Approaches used for Targeted Drug Delivery to 
Colon: 
7.1.1 Liposomes: These consists vesicles which are 
spherical in shape and are made up of phospholipid bilayers. 
They are said to be a good drug delivery system for drugs 
with various physicochemical properties [54]. As drug 
delivery, liposomes offer certain benefits like the capacity to 
enclose both hydrophilic and lipophilic drugs 
biodegradability, biocompatibility and other nontoxic 
properties [55,56]. In order to improve liposomal drug 
delivery to the tumor site, targeting approaches with the 
conjugation of ligands to the surface of liposomes have been 
extensively studied. There are various patterns of cell death 
when the cells are exposed to anticancer drugs. Many cell 
death related to transduction pathways are aided by the 
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function of   mitochondria [57]. Apoptosis plays a vital part  
in response to regulatory signals which can be either stress 
induced or can be of other type .  There are two major types 
of   pathways which lead to apoptosis : the intrinsic 
(mitochondrial) pathway and the extrinsic (death receptor) 
pathway. The mitochondrial  pathway is activated by 
different types of stimuli like  intracellular stimuli which 
includes DNA damage, oxidative stress and growth factor 
deprivation. The extrinsic pathway of apoptosis is started  by 
the binding of death ligands such as Fas ligand and TNF-α to 
death receptors of the TNF receptor super family [58]. 
Reactive oxygen species (ROS) is an important parameter 
associated with cell death. The value of ROS may decide 
between necrosis and apoptosis [59]. It has been earlier seen 
that little or high levels of ROS manage the apoptotic and 
necrotic pathways, respectively [60].  
The therapies based on the Fluoropyrimidine like 
administration of 5 FU are the treatment approaches in 
metastatic CRC [61]. Because of the similarity in structure to 
the pyrimidine base of DNA and also it is an antimetabolite 
that acts via inhibiting essential processes for tumor cell 
proliferation such as DNA and RNA synthesis, 5FU interferes 
with the metabolism of nucleoside, resulting in cytotoxicity 
and finally cell death [62]. However, clinical applications of 
5FU have certain limitations like short half-life (20 
min)because of the fast metabolism and nonspecific drug 
distribution causing toxicity on the gastrointestinal tract, 
bone marrow cells, and  other dermatological effects [63]. 
Therefore, various methods have been taken to enhance the 
delivery of 5FU so as to increase therapeutic index with a 
decrease in side effects. Encapsulation of 5FU in 
nanoparticles, such as liposomes, can lessen the clearance of 
the drug and decrease the associated toxicity [64]. This drug 
being highly catabolized (more than 80%) through the 
activity of the dihydropyrimidine dehydrogenase in the liver 
[65]. Therefore, tumor-targeted delivery of 5-FU is an 
important idea  for increasing  the therapeutic index of this 
agent. Moreover, earlier  studies have shown  that tumor-
targeting properties of LCL (Long-Circulating Liposomes) 
could permit various  cytotoxic drugs such as paclitaxel, 
cisplatin etc. to gather into the tissues [66] of the tumour  
and acted more effectively when  compared to conventional 
chemotherapy system which is  based on the free taking  of 
the same drugs. Thus, LCL as nanovehicles for 5-FU will 
make a sure passive gathering  in solid tumors, because of 
the unusual characteristics  of the tumor vasculature  also 
called  as EPR (Enhanced Permeability and Retention) effect 
[67,68]. The LCL encapsulated 5-FU (LCL-5-FU) can also help 
in reducing the drug toxicity on healthy tissues. The 
combination of LCL-5-FU with LCL containing PLP (LCL-PLP)  
has  inhibitory effects in colon carcinoma in vivo [69] caused 
by tumor angiogenesis suppression [70] and can help in the  
improvement of  CRC treatment. To compare the antitumor 
activity of combined liposomal drug therapy based on 
simultaneous administration of 20 mg/kg LCL-PLP and 1.2 
mg/kg LCL-5-FU with that induced by liposomal 
monotherapy (either 20 mg/kg LCL-PLP or 1.2 mg/kg LCL-5-
FU) on the growth of C26 colon carcinoma in vivo, mice were 
injected i.v. when tumor volumes were about 200 mm3 (at 
day 8) and at day 11 after tumor induction. The same dosing 
schedule and treatment schemes were employed when the 
drugs were administered as free forms. The study of Laura P. 
et al; showed that the growth of C26 colon carcinoma was 
affected fairly when LCL-5-FU was given  (by 53%, P < 0.01) 
to strongly when LCL-PLP treatment was done  (by 70%) 
when compared to control tumors (PBS-/LCL-treated 
groups) growth according to tumor volumes measurements 
at scarification day [71]. 
Eskandar M., Mohsen R., et al; found that 5FU entrapment 
efficiency can be increased by increasing the number of 
phospholipids. So if we raise the number of phospholipids, 
liposomes came out to be more rigid with the capacity to 
keep more drugs [72]. The cytotoxicity of 5FU, liposomal 
5FU, and Tf-liposomal 5FU was checked by MTT assay which 
is based on the capacity of succinic dehydrogenase enzyme 
of living cell to changing the color from yellow to dark purple 
[73]. HT-29 cells and fibroblast cells were taken as colon 
cancer cell lines and normall cells respectively to check 
whether targeted liposome has a cytotoxic effect on normal 
cells. The IC50 values for 5FU, liposomal 5FU, and Tf-
liposomal 5FU were 66.069, 58.88 and 31.62μm, 
respectively. Also, see that no major difference was seen in 
the cytotoxicity of 5FU and liposomal 5FU that might be 
because of the internalization of nontargeted liposome inside 
the cells. This finding showed that targeted liposomal 
formulations with Tf altered the cellular uptake of the 
liposomes but also caused the better gaining of therapeutic 
effect with a decrease in the dose of 5FU. This finding 
confirms previous research of Sun et al and Zhang et al and 
Singh et al. Furthermore, Tf-liposomal 5FU induced 
apoptosis in cancer cells by lower production of ROS, 
decreased ΔΨm and higher release of cytochrome c. It is 
concluded that Tf targeted liposomes would provide a 
promising therapeutic approach for cancer. The ΔΨm 
(mitochondrial membrane potential) of HT-29 cells treated 
with the free drug and Tf-liposome 5FU was 0.18% and 
6.36%, respectively. 
Statins- The cholesterol-lowering agents can be utilized as 
anticancer drugs, because of the uppressive action on the 
making of isoprenoids, products of mevalonate pathway – 
responsible for the posttranslational alteration of a series of 
G protein associated with the  cancer cell proliferation 
[74,75]. The study was done to investigate whether colon 
carcinoma – specific delivery of SIM by utilizing long - 
circulating liposomes (LCL) might be a solution for the need 
of high doses of this statin to obtain antitumor action while 
decreasing the side effects on healthy tissue. Passive tumor 
targeting of SIM was checked by the long-circulating ability 
of PEG coated liposomes . SIM-LCL with PEG coating because 
of EPR effect gathered in malignant tissue [76]. The 
maximum antitumor activity was obtained at a dose of 5 
mg/kg. Tumor volumes were decreased with more than 70%  
at this dose and the slowing down  of tumor growth at day 16 
after tumor induction was around  62%  when checked  with 
the growth of control group.5mg/kg LCL-SIM and the same 
dose of free SIM on c26 colon carcinoma-bearing mice, 
treatments were given. Volume doubling time (DT) of tumor 
established the inhibitory action of LCL-SIM on tumor 
growth since DT for c26 tumors that obtained the liposomal 
treatment was about 2 times longer than DT of tumors from 
free SIM-treated group or control group [77]. 
Standard cytotoxic agents for CRC are 5FU, often taken 
together with irinotecan and oxaliplatin [78]. In patients 
with the advanced disease, almost all patients still develop 
resistance to treatment and succumb to tumor growth. 
Targeted antibodies are regularly used in treating mCRC, 
including agents that target vascular endothelial growth 
factor (VEGF) and its receptor (VEGFR) [79]. Targeting of 
VEGF pathways in CRC is designed to reduce tumor blood 
supply by disrupting tumor vessels, and has had some 
success in the clinic [80]. One such therapy is bevacizumab, a 
VEGF-targeted monoclonal antibody, which has been 
approved for CRC patients in combination with various 
chemotherapy regimens. Most of the therapeutic options in 
CRC have the problem of resistance in the clinic because of 
the to the heterogeneous nature of tumors of the colon [81]. 
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Clinical trials using LP for CRC treatment focus mainly on the 
delivery of the well-characterized drug, including irinotecan 
and its metabolites, doxorubicin. LP deposition in solid 
tumors is heavily influenced by EPR, making the state of 
tumor blood vessels a key factor in delivery. Short-term bev 
resulted in significantly smaller vessel diameter compared to 
untreated controls. The total tissue area occupied by CD34+ 
vessels in treated tumors was 3.8%±1.5% compared to 
5.7%±1.7% in control tumors [82].    
7.1.2 Nanoparticles: 
The preparation of nanoparticles [83] is simple and these are 
useful in preserving the protein and peptide drugs from the 
chemical and enzymatic degradation in GIT resulting in an 
enhancement in their stability and absorption of through the 
intestinal epithelium. The methods include the involvement 
of organic solvents, heat, and agitation. The disadvantage of 
these methods is that the heat is causing damage to the 
proteins and peptide drugs [46]. Ionic gelation method is 
used for proteins and peptide drugs. The use of nanoparticles 
(NPs) in the treatment of cancer treatment works on EPR 
effect to tumor tissues [84]. Due to irregular leaky 
vasculature and damaged lymphatic drainage in the tumors, 
NPs can be punctured in the tumor tissue and release the 
drug at particular areas; as a result, to decrease the exposure 
to normal tissues, and reduce the side effects. NPs can be 
further altered by targeting ligands [85]. Antibodies, 
carbohydrates, peptides, folate acid (FA) and transferring are 
among the several ligands to target cancer cells [86]. 
Le et al. in 2015 prepared 5FU loaded folate targeted 
nanoparticles. They reported that there was no significant 
difference between the cytotoxicity of 5FU and 5FU loaded 
NPs on cancer cells. The cytotoxicity of folate targeted NPs 
was significantly increased compared to free drug and non-
targeted NPs. The NPs having the size around 100 to 200 nm 
gathered much efficiently in solid tumors than normal 
tissues. They also said that folate-targeted NPs might enter 
inside the tumor cells by endocytosis which is mediated 
through folate receptor [87]. They have seen that the 
addition of free folic acid to the folate-free culture medium of 
CT26 cells, cell viability was enhanced to 51.98 ± 6.3%. 
These results showed that the free folic acid stopped the FR-
dependent binding and uptake of NPs, which showed that the 
folic acid targeted NPs were up taken [88]. Lv et al. showed 
that capsaicin loaded folate-targeted NPs showed a 
remarkably higher toxic effect compared to non-targeted 
NPs. They showed that the anticancer action of drug loaded-
targeted NPs are because of the cellular uptake of NPs via 
FRs-mediated endocytosis pathway [89]. 
Selenium nanoparticles cause the chemo-sensitivity of 5-
fluorouracil (FU)-encapsulated poly (D, L-lactide-co-
glycolide) nanoparticles (nano-FU) in colon cancer and 
breast cancer cell lines. Nano-Se and nanoFU were made and 
checked, then used individually or in combination upon 
MCF7, MDA-MB-231, HCT 116, and Caco-2 cancerous cell 
lines. Cytotoxicity, cellular glucose uptake, and apoptosis, as 
well as malondialdehyde (MDA), nitric oxide (NO), and zinc 
(Zn) levels were investigated upon the different treatments. 
The results revealed a dose-dependent decrease in cell 
viability of MCF7 and MDA-MB-231 cancerous cell lines, with 
a little bit increase in cytotoxicity when comparing MCF7 and 
Caco-2 with MDA-MB-231 and HCT 116 lines. Furthermore, 
FU and nano-FU had the highest cytotoxic effects at 50μm 
with 80.9 and 78.8% of MDA-MB-231 cell viabilities, 
respectively, while 62.0 and 60.3% of MCF7 cell viabilities, 
respectively, at 24 h. On the other hand, FU and nano-FU had 
the highest cytotoxic effects at 50μm with 77.7 and 83.0% of 
HCT 116 cell viabilities, respectively, while 69.1 and 66.9% 
of Caco-2 cell viabilities, respectively, at 24 h [90]. 
The capecitabine nanoparticles (CB-SLNs) were prepared by 
the microemulsion method. From the results, Cmax and tmax of 
the SLN and suspension formulation were found to be 
6.81±0.63 and 3.19±0.47 µg/mL; 2±0.0 and 1±0.0 h, 
respectively. 
The hyaluronic acid (HA)-conjugated mesoporous silica 
nanoparticles(MSN) loaded with 5-fluorouracil (5-FU) was 
prepared to increase the anticancer efficacy in colon cancers. 
The presence of HA on the surface of nanoparticles targeted 
the CD44 receptors overexpressed in the colon cancer cells. 
HA/FMSN resulted in higher around  43% of cells in the 
starting of the apoptosis phase and 55% of cells in late 
apoptosis phase showing the great anticancer effect of HA/ 
FMSN. HA/FMSN showed a major decrease in the tumor 
burden when the comparison was done with any of that of 
the group. HA/FMSN was 3-fold more effective than free 
drug and 2-fold more effective than -FU loaded mesoporous 
silica nanoparticles (FMSN). 
7.1.3 Monoclonal antibodies: 
We have recently demonstrated that the atypical cadherin 
FAT1 is a particular marker of CRC and that the FAT1-
specific monoclonal antibody mAb198.3 may provide a new 
therapeutic opportunity for CRC, being nicely internalized by 
cancer cells and decreasing cancer growth in colon cancer 
xenograft models. In this study, we checked the therapeutic 
effect of mAb198.3 utilizing the two drug delivery systems 
(DDS) for enhancing the targeted management of CRC. The 
mAb198.3 can directly attach to super-paramagnetic 
nanoparticles (spmNPs) or embedded into erythrocyte-
based carriers, named Erythro-Magneto-Hemagglutinin 
Virosomes (EMHVs) to produce two different novel 
mAb198.3 formulations. Both DDS have magnetic properties 
and were harbored in the target tumor region with the help 
of an external permanent magnet. mAb198.3 and its isotype-
matched antigen-unrelated control (isomAb) were 
crosslinked l of spmNP [90]. A final concentration of 1.2µg in 
200µl of spmNP suspension was achieved for either of the 
two antibodies. The mAb198.3-spmNP formulation was 
compared to free mAb198.3 in terms of ability to bind the 
FAT1-positive HCT15 colon cancer cell line, by using flow 
cytometry.  mAb198.3 (300 μg/dose) induced a significant 
anti-tumor effect, expressed as normalized tumor mass 
volume, starting from the 5th injection with respect both to 
equivalent free isomAb and control (two ways ANOVA RM p< 
0.003) although mAb198.3-spmNP formulation employed an 
antibody dosage at least 300 fold lower than the free 
mAb198.3 treatment. These results indicate an improvement 
in terms of pharmacodynamics of mAb 198.3 formulated 
with the magnetic nanoparticle carrier. 
7.1.4 Prodrug: 
It is the inactive type of an active parent drug that goes 
through a transformation which is mainly enzymatic to 
release the active drug. The different carriers used for 
prodrug linkages are described in table4. Gal-Dox was 
synthesized by following a series of steps in good to excellent 
yield [91]. Administration of Gal-Dox showed remarkable 
tumor growth inhibition (53.1 %) compared to free Dox 
treatment (34.9 %, see Fig. 5D). Although Dox has been 
known to have several adverse effects such as cardiotoxicity, 
no significant in vivo toxicities were observed during this 
study. 
The xylan-5-fluorouracil-1-acetic acid (Xyl-5-FUAC) 
conjugates as colon-specific prodrugs were synthesized. The 
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chemical stability of the conjugates was performed in acidic 
(pH 1.2) and basic buffers (pH 7.4), which showed their 
stability in the upper gastrointestinal tract. The in-vitro drug 
release profiles of the conjugates were studied in the 
presence of rat’s gastrointestinal contents [92]. The results 
showed that the low amounts of drug 3-4% and 5-7% were 
released in gastric and small intestine contents respectively, 
while 53-61% of the drug was released in the caecum and 
colonic contents. The cytotoxicity studies of the conjugates 
were checked on human colorectal cancer cell line (HTC-15 
and HT-29), and it was seen that the conjugates were more 
cytotoxic when compared to the free drug. Finally, the results 
showed that the Xyl-5-FUAC conjugates can be used for 
colon-specific drug delivery in the treatment of colonic 
cancer with decreased side effects [93]. In this IC50 of 5-FU 
against HT-29 cells (i.e. 4.545 (μg/ml) declined drastically to 
a value of 1.818 (μg/ml) and 1.454 (μg/ml) in case of Xyl-
5FUAC (1:1) and Xyl-5-FUAC (1:2) respectively. Similarly in 
case of HCT-15 also 5-FU, IC50value declined from 2.54 
μg/ml to 2.09 μg/ml and 1.727 μg/ml for Xyl-5-FUAC (1:1) 
and Xyl-5FUAC (1:2) respectively. 
 
Table 4: Examples of Prodrug system for CDDS 
Drug Carrier Linkage hydrolyzed 
5-ASA Azo conjugates Azo linkage 
Dexamethasone Saccharide carriers Glycosidic linkage 
Prednisolone, hydrocortisone, fludrocortisones Glucose, galactose Glycosidic linkage 
Salicylic acid Amino acid conjugates, glycine Amide linkage 
 
 
 
 
 
 
                                 
                 
 
 
 
 
 
Figure 3: Mechanism of internalization of different targeted drug carries. 
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